Information Provided By: 
Fly News Breaks for October 5, 2016
JAZZ
Oct 5, 2016 | 07:33 EDT
BMO Capital analyst Gary Nachman said recent Jazz Pharmaceutical management meetings confirm his positive thesis and said risk/reward in shares is favorable at current levels. Nachman said management sounded very confident in the company's outlook and he remains optimistic that a favorable Xyrem settlement would lift a significant overhang on the stock and help unlock untapped value with the pipeline. The analyst reiterates his Outperform rating and $195 price target on shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
